Junshi Biosciences (01877.HK): The marketing application for a new indication of toripalimab injection (subcutaneous injection) for first-line treatment of HER2-expressing urothelial carcinoma has been accepted.

Zhito Finance APP News, Junshi Biosciences (01877.HK) announced that recently, the company received the "Notice of Acceptance" issued upon approval by the National Medical Products Administration. The marketing application for a new indication of the company's product toripalimab injection (subcutaneous injection) (code: JS001sc) in combination with disitamab vedotin for the treatment of HER2-expressing (HER2 expression defined as HER2 immunohistochemistry results of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma has been accepted. The marketing applications of toripalimab injection (subcutaneous injection) covering all 13 approved indications of toripalimab injection (trade name: Tuoyi, code: JS001) have all been accepted.